Survival Strategies

/Survival Strategies

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47-04:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|

First GDOL Chicago hits a homerun!

Our first Chicago GIST Day of Learning (GDOL) was a huge success! Over 50 GISTers and their families gathered for a great day of learning, and sharing experiences. It was wonderful to get to meet so many new people and reconnect with old friends.

By |2016-04-01T14:42:00-04:00June 11th, 2013|GIST Education, Gleevec, News, Patient Support, Survival Strategies|

LRG Launches Mutational & Plasma Level Testing Survey Project

Recently, the Life Raft Group began work on a survey project sponsored by Novartis Pharmaceuticals designed to assess knowledge and practices among patients and physicians regarding mutational analysis and plasma level testing.

By |2019-04-08T08:49:37-04:00October 1st, 2011|Mutational Testing, News, Survival Strategies|

Mutational Testing & Survival: Where We Stand

Only six percent of GIST patients in the United States take advantage of testing that could be used to individualize their treatment according to a new article in the Annals of Oncology. Dr. Peter Pisters of MD Anderson Cancer Center in Houston, Texas and his colleagues reported results of the GIST reGISTry, a Novartis Pharmaceuticals-supported registry of 882 GIST patients in the United States.

By |2019-04-05T09:52:42-04:00June 1st, 2011|Mutational Testing, News, Survival Strategies|

PDGFRA Mutations: It’s time to consider mutational status for resistant GIST patients

January 6th, 2011 - By Jerry Call,  LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open [...]

It’s Time to Consider Mutational Status for Resistant GIST Patients: KIT exons 9 & 11

KIT exon 11 and exon 9 mutations represent the two most common types of mutations (wild-type GIST is technically not a type of mutation but a lack of mutations) found in GIST patients. About 60 to 65 percent of GIST patients have a KIT exon 11 mutation and about 10 to15 percent have a KIT exon 9 mutation.

By |2018-12-20T10:24:33-04:00February 1st, 2010|Mutational Testing, News, Survival Strategies|

Recent Posts

Upcoming Events

  1. Kathy Sarmiento Medicare 101 Webcast

    LRG Webcast Series: Medicare 101

    September 9 @ 12:00 PM - 1:00 PM
  2. GDOL Ottawa logo

    GIST Day of Learning – Ottawa

    September 28 @ 9:00 AM - 4:30 PM